Histamine is one of the most important biogenic amines and it mediates numbers of physiological processes. It is also involved in majority of inflammatory diseases via its receptors H 1 , H 2 , H 3 and H 4 . The role of histamine had been recognized as substantial in many allergic diseases including bronchial asthma, thus the histamine receptor antagonists (H 1 ) are frequently used in the clinical practice as potent anti-allergic and anti-inflammatory drugs.
INTRODUCTION
Histamine plays a prominent role in the pathophysiology of allergic diseases, asthma, rhinitis and urticaria (1, 2, 3) . In human pathology, histamine triggers acute symptoms via its very rapid action on vascular endothelium and bronchial smooth muscle cells, leading to the development of acute symptoms such as nasal discharge, nasal congestion, bronchoconstriction, abdominal cramps, diarrhoea or skin wheal and a flare response. Moreover, in addition to these effects on the immediate-type response, histamine also significantly modulates chronic phase of inflammatory processes (4) .
In fact, these data would be shared probably by majority of medical students, or health care professionals, because the role of the histamine in inflammation and allergies is well recognized and described. However, there is still a potential in further research of histamine action, mainly in central nervous system. The role of histaminergic neurons, their function and relevance are not well established. Except of central nervous system, H 3 receptors are involved in many processes outside of it, for example mast cell-neuron loop in the tissues, where H 3 receptors regulate intensity of neurogenic inflammation. Histamine H 3 receptor and its antagonists may have clinical applications in treatment of diseases induced or influenced by the action of histaminergic neurons, thus leading to limited availability of certain neuromediators. The aim of this short review is to focus on less known histamine receptor H 3 and its relevance for human physiology and pathophysiology.
HISTAMINE AND ITS ACTION
Histamine (2-[4-imidazolyl] ethylamine), is a biogenic amine, that was isolated from the mould ergot in 1910 by Sir Henry Dale and his colleagues at the Wellcome Laboratories. Afterward they found that it stimulated smooth muscle from the gastrointestinal and respiratory tract, it induced vasodilatation and stimulated cardiac contractility. Finally, it induced a shock-like syndrome when injected into animals (5, 6) . In 1920, Popielski demonstrated that histamine has a marked stimulating effect on the secretion of acid from the stomach of dogs (7) . In 1924, Lewis described the classic 'triple response' to histamine consisting of a red spot due to vasodilatation, a wheal which was the consequence of increased permeability and a flare due to an axon reflex (8) . Histamine was identified as a mediator of anaphylactic reactions in 1932 (9) . In 1927, Best et al. (10) isolated histamine from samples of liver and lungs, and later from other tissues, hence, the name histamine was given after the Greek word for tissue, histos. Since that time there has been a growing pool of data about the action of histamine, histamine receptors, their intracellular signaling pathways and potent antagonists with clinical application.
Histamine is synthesized by the pyridoxal phosphate-containing L-histidine decarboxylase (HDC) from the amino acid histidine (11) . Gastric enterochromaffin-like cells, histaminergic neurons as well as mast cells and basophils are classical cellular sources of histamine, where it is stored in intracellular vesicles and released on stimulation. Several haematopoietic cell lines have been shown to synthesize histamine, but 100-1000-fold less than mast cells and basophils. De novo histamine synthesis has also been shown in other cell types, such as platelets, monocytes/macrophages, dendritic cells, neutrophils and lymphocytes (12, 13, 14) .
The major routes of histamine inactivation in mammals are methylation of the imidazole ring, catalyzed by histamine N-methyltransferase (HNMT), and oxidative deamination of the primary amino group, catalyzed by diamine oxidase (DAO) also known as histaminase (15) . The DAO protein is stored in plasma membrane-associated vesicular structures in epithelial cells and is secreted into the circulation on stimulation (16, 17) . In mammals, DAO expression is restricted to specific tissues; the highest activities are shown for small intestine, ascending part of colon (18, 19) and for placenta and kidney (16, 20) . Conversely, HNMT is a cytosolic protein (21) , which can convert histamine only in the intracellular space of the cells (20, 22) . HNMT is widely expressed in human tissues; the greatest expression is in kidney and liver, followed by spleen, colon, prostate, ovary, spinal cord cells, bronchi, and trachea (23) . HNMT is regarded as the key enzyme for histamine degradation in the bronchial epithelium (24) .
Histamine is a potent mediator of numerous biologic reactions. Besides the well-known triggering of mast cells degranulation by crosslinking of the Fc RI receptor by specific allergens, several other non-immunologic stimuli, such as neuropeptides, substance P, complement factors (i.e., C3a and C5a), cytokines (IL-1, IL-3, IL-8, GM-CSF), platelet-activating factor (PAF), hyperosmolarity, lipoproteins, adenosine, superoxidases (25) , hypoxia, chemical and physical factors (e.g., extreme temperatures, traumas, vibration) (26), or alcohol and certain food and drugs, may activate mast cells too (27, 28) . The pleiotropic effects of histamine are triggered through one or several histamine receptors on different cells. Four subtypes of receptors (histamine 1 receptor (H 1 R), histamine 2 receptor (H 2 R), histamine 3 receptor (H 3 R), and histamine 4 receptor (H 4 R) have been described. All these receptors belong to the G-protein-coupled receptor family. They are heptahelical transmembrane molecules that transduce the extracellular signal by using G-proteins and intracellular second messenger systems (29, 30) . Differences in the affinities of these receptors are highly decisive on the biological effects of histamine and agents that target.
HISTAMINE RECEPTORS
Histamine has diverse actions in the human body, and those are influenced by several factors. One of the determining factors governing the histamine action is the type of receptor mediating the signal transduction. Basically, the knowledge on histamine receptors classifies four types of them with different expression pattern within the body and main actions they are capable to induce (Table 1) .
The active and inactive states of HRs exist in equilibrium. However, it has been shown in recombinant systems that HRs can trigger downstream events in the absence of receptor occupancy by an agonist, which accounts for constitutive spontaneous receptor activity (31) .
HR agonists stimulate the active state in the receptor and inverse agonists stimulate the inactive one. An agonist with a preferential affinity for the active state of the receptor stabilizes the receptor in its active conformation leading to a continuous activation signal. An inverse agonist with a preferential affinity for the inactive state stabilizes the receptor in this conformation and consequently induces an inactive state, which is characterized by blocked signal transduction via the HR (32). HR antagonists block receptor sites causing no action at that receptor since agonists can't bind.
HRs form dimers and even oligomers, which allow cooperation between HRs and other Gprotein-coupled receptors. The affinity of histamine to different HRs varies significantly, with Ki values ranging from 5-10 nM for the H 3 and H 4 receptors to 2-10 mM for the H 1 and H 2 receptors (11, 33) . Specific activation or block of HRs showed that they differ in expression, signal transduction or function and improved the understanding of the role of histamine in physiology and disease mechanisms (4) . Histamine can act not only on cell surface receptors (H 1 , H 2 , H 3 and H 4 receptors), but may also bind to some "intracellular receptors" such as cytochrome P450 and cytochrome c (34, 35) and high-affinity lipocalins isolated from the saliva of ticks (36) . The histamine H 3 receptor (H 3 R) was first identified by Arrang and colleagues in 1983 using a functional assay. It was found that histamine inhibits its own synthesis and release (38) . The cloning of the histamine H 3 receptor (H 3 R) cDNA in 1999 by Lovenberg et al. (39) allowed detailed studies of its molecular aspects and indicated that the H 3 R can activate several signal transduction pathways (Figure 2 ) including G i/o -dependent inhibition of adenylyl cyclase, activation of phospholipase A 2 , Akt and the mitogen activated kinase as well as the inhibition of the Na + /H + exchanger and inhibition of K + -induced Ca 2+ mobilization. Moreover, cloning of the H 3 R has led to the discovery of several H 3 R isoforms produced by alternative splicing of the H 3 R mRNA (40). The human and rat H 3 receptors exhibit a 97% homology in the transmembrane domains, but surprisingly they display a significant difference in the affinity for some H 3 ligands (e.g. thioperamide shows a tenfold preference for the rat receptor). Single form of the H 3 gene can give rise to multiple mRNA isoforms, named H 3A , H 3B and H 3C in the rat (41) and H 3L and H 3S in the guinea pig (42) . 
NEURONAL H 3 R
H3R is expressed in many brain areas including cerebral cortex, hippocampus, amygdala, nucleus accumbens, globus pallidus, striatum and hypothalamus. The H3R acting as presynaptic autoreceptor on the neurons (inhibits release of histamine from histaminergic neurons) and heteroreceptor expressed in non-histamine-containing neurons in the central and peripheral nervous systems, where it inhibits release of other neurotransmitters such as acetylcholine, noradrenaline, dopamine, and serotonine ( Figure 3) (39, 43) .
Abbreviations: H 1 R -histamine H 1 receptor, H 2 R -histamine H 2 receptor; H 3 R -histamine H 3 receptor, G-G protein, cAMP -cyclic adenosine monophosphate, ctx -cortex, HDD -histamine decarboxylase, hip -hippocampus, hyp -hypothalamus, IP 3 -inositol triphosphate, DAGdiacetyl glycerol, loccor -locus coeruleus, -na -nucleus accumbens, nbs -nucleus basalis magnocellularis, pvn -paraventricular nucleus, sn(pr) -substantia nigra (pars reticulata), str -striatum, vta -ventral tegmental area.
Both histamine and the neurotransmitters regulated by it participate in many important physiological functions. Histamine synthesizing neurons are located in the tuberomammillary nucleus of the hypothalamus and project widely throughout the brain to regions that include the cortex, the hippocampus, amygdala and striatum (45) . The central histaminergic system is involved in many central nervous system functions: sleep-wake cycle, arousal, anxiety, activation of the sympathetic nervous system, cognition, learning, memory, the stress-related release of hormones from the pituitary and of central aminergic neurotransmitters, antinociception, water retention and suppression of eating, through the four receptors subtypes: H 1 , H 2 , H 3 and H 4 (45, 46) . Acetylcholine plays an important role in cognitive functions, and noradrenaline has become recognized as playing a large role in attention and focus. Since the H 3 R regulates the levels of these important neuronal agents, it has become an attractive target for developing treatments for variety of neurological disorders (47) .
H 3 antagonists are potential drugs for the treatment of disorders connected to cognitive processes and alertness, such as, excessive daytime sleepiness with Parkinson patients, narcolepsy, Alzheimer's disease, attention-deficit hyperactivity disorder, epilepsy, and schizophrenia (44, 48) . Moreover, histamine via H 3 receptors can also decrease blood brain barrier permeability and mitigate against early phase neuroinflammation (49). Examples of histamine H 3 R antagonists and agonist are summarized in Table 2 , documenting huge research in this area, and availability of many H3R relevant molecules for research purposes. Histamine H 3 receptors (H 3 Rs), distributed within the brain, the spinal cord, and on specific types of primary sensory neurons, can modulate pain transmission by several mechanisms. In the skin, H 3 Rs are found on certain Aβ fibers, and on keratinocytes and Merkel cells, as well as on deep dermal, peptidergic Aδ fibers terminating on deep dermal blood vessels. Activation of H 3 Rs on the latter in the skin, heart, lung, and dura mater reduces calcitonin gene-related peptide and substance P release, leading to anti-inflammatory (but not antinociceptive) actions. However, activation of H 3 Rs on the spinal terminals of these sensory fibers reduces nociceptive responding to low-intensity mechanical stimuli and inflammatory stimuli such as formalin (50) .
PRESYNAPTIC MODULATION IN AUTONOMIC NERVOUS SYSTEM
Visceral organs are widely innervated by the fibres of autonomic nerves with many ganglia located within the wall of dull organs such as esophagus or stomach. Functions of these organs are regulated by the way of neurotransmitter releases from the nerve fibers they have on target effectors -muscles, glands etc. There are numerous reports of presynaptic H 3 receptors in the autonomic nervous system controlling neurotransmitter release in the heart, the lung, and the gastrointestinal tract (39).
In the gastrointestinal tract H 3 receptors are located in cholinergic and non-adrenergic non-cholinergic (NANC) neurons of the myenteric plexus, in endocrine and/or paracrine cells of the gastric mucosa and, at least in rabbits, also in parietal cells (51) . H 3 receptors are mainly located on histamine-producing cells, where they work as an endogenous inhibitory mechanism operated by histamine itself to control excess acid production. H 3 receptor agonists combine antiinflammatory properties with antisecretory and gastroprotective effects (52) .
MODULATION OF ADRENERGIC RESPONSES IN THE HEART
H 3 -receptors are present in sympathetic nerve endings in the human heart, where they modulate adrenergic responses by inhibiting noradrenaline release (53) . In severe myocardial ischemia, H 3 R activation affords cardioprotection by preventing excessive noradrenaline Cardioprotection ultimately results from the combined attenuation of angiotensin II and noradrenaline effects and alleviation of arrhythmias (54) .
UPPER AND LOWER AIRWAYS
It is well known that histamine plays an important role in eliciting the nasal symptoms of allergic rhinitis; i.e., pruritus, sneezing, rhinorrhea, and congestion (55) . H 3 R plays a role in mucus secretion in the nasal submucosal gland. H 3 R plays a role in allergic rhinitis, and expression of H 3 R increases during allergic rhinitis (56).
Nakaya et al. (57) used immunohistochemistry to examine distribution of histamine receptor subtypes in the human inferior turbinates, and reported that H 4 R and H 3 R were clearly expressed on nerves in the human inferior turbinates. They demonstrated that H 3 R protein was expressed on the nerve bundle, rather than on the nerve terminals. Stimulation of H 3 R expressed on sympathetic nerve terminals inhibits release of noradrenaline from those nerves. In the absence of histamine, noradrenaline released from sympathetic nerve terminals helps to maintain normal vascular tone. The presence of histamine decreases noradrenaline levels, causing vasodilatation leading finally to nasal obstruction (58) . In the human lower airways, H 3 R regulates cholinergic nerve transduction (59). In guinea pigs, H 3 R is present on the vagus nerve, which modulates cholinergic neurotransmission in the airways (60) .
H 3 -receptors presented in the vagal pathway inhibit acetylcholine release and could play a role in modulating neural bronchoconstriction in allergic disease when histamine is released from airway mast cells in the vicinity of airway ganglia and cholinergic nerves (60) .
The control of mast cells by histamine acting on H 3 R involves neuropeptide-containing nerves and might be related to a local neuron-mast cell feedback loop controlling neurogenic inflammation (61) . Dysregulation of this feedback loop may lead to excessive inflammatory responses and suggests a novel therapeutic approach by using H 3 R agonists (4).
CONCLUSIONS
As it could be seen from this short overview, there is a growing pool of data indicating that histamine and particularly histamine H 3 receptors are constantly under the scope and they are studied in relation to many aspects. Very strong aspect is the role of histaminergic neurons in onset, development and progression of certain neurologic disorders as they have been described above. Also interesting and very strong side of H 3 R antagonists could be the field of antinociception. The fact they are abundant in autonomic nerves within visceral organs makes it possible targets for visceral pain, mechanisms of which are still not satisfactorily explained. Primary interest of our research is respiratory system, allergic rhinitis, asthma and cough. This is also the main reason we studied H 3 receptors to see possible involvement of H 3 antagonists in models of airway diseases. As long as we know, there are some H 4 antagonists at the very beginning of clinical trials but no H 3 antagonists so far.
We do believe that every single effort counts in the process of searching for effective enough but safe treatment for our patients and that is also the reason we will focus further attention on H 3 receptors in our future research. 
